Cancer Immunotherapy Firm Soars on FDA Nod, Prescribes 191% Gains

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

While most silver miners are cutting back or struggling to scale, one pure-play silver producer is already firing on all cylinders.

Four producing mines.

Over 7.7 million silver-equivalent ounces delivered in Q1.

Full-year output expected to hit 30–32 million.

They’re also capturing value most producers miss—selling branded silver bars and coins directly to investors through their own U.S.-based mint.

It’s a full-stack silver model: mine, mill, mint, and margin.

As silver enters the vertical phase of its cycle, this could be one of the best-positioned names in the sector.

Get the details before it breaks wide open.

U.S. equities declined on Tuesday as investors reacted to weak retail sales data and the escalating conflict between Israel and Iran, with President Donald Trump calling for Iran’s unconditional surrender.

Coinbase (NASDAQ: COIN) has taken a bold step by seeking approval from the U.S.

Securities and Exchange Commission to offer tokenized equities digital tokens that represent ownership in traditional stocks.

The move signals Coinbase’s ambition to go beyond crypto trading and enter mainstream equity markets using blockchain technology.

If granted, this would enable the platform to offer stock trading via blockchain, placing it in direct competition with major brokerages while potentially generating a new revenue stream.

The company’s request, if successful, could lead to faster settlements, reduced costs, and round-the-clock trading features that would appeal to a broad base of investors.

For current shareholders, this signals a potentially game-changing business expansion that could diversify Coinbase’s earnings beyond cryptocurrency.

It shows the company’s focus on innovation and regulatory engagement, key factors as the crypto sector seeks greater legitimacy.

Existing investors should monitor how regulators respond, as this could mark the start of a significant growth phase.

Those evaluating Coinbase as a potential investment may consider the risk-reward dynamics.

While the opportunity is sizable for creating a new digital stock marketplace, the uncertainty surrounding regulatory approval remains a significant hurdle.

How quickly Coinbase can secure the necessary permissions will be critical to unlocking this new growth path.

Coinbase’s move comes as competitors globally explore similar offerings, positioning the company to be an early leader if approved.

The SEC’s decision will be closely watched by markets looking for signs of innovation in equity trading.

Markets are on edge as tensions rise between two of America’s most powerful figures—Trump and Musk.

With inflation rising, banks pulling back, and stocks swinging wildly, retirement accounts are more exposed than ever.

But one asset class has quietly gained value during every major crisis: physical gold.

Discover how to protect wealth and roll over eligible accounts into gold—without paying taxes or penalties.

CLAIM YOUR FREE GOLD IRA GUIDE NOW

The window to protect your wealth is closing fast. Act now before the next headline sends markets into freefall.

Kraft Heinz (NASDAQ: KHC) is making its biggest shift in years as it moves to eliminate artificial dyes from all U.S. products by the end of 2027.

The company announced that it will stop using FD&C synthetic colors in household names such as Kool-Aid, Jell-O, MiO, and Crystal Light.

This marks a major step in responding to growing regulatory pressure and changing consumer expectations.

For shareholders, this signals Kraft Heinz’s attempt to position itself as a trusted leader in healthier food options.

The move shows that the company is not just reacting to new FDA guidelines but aiming to stay ahead of a broader industry shift toward cleaner ingredients.

While this transition may involve some near-term costs and manufacturing adjustments, it aligns with the growing demand for transparency and wellness in the food sector.

Investors should monitor how this impacts brand loyalty and sales as the phase-out progresses.

Kraft Heinz says it plans no new U.S. product launches with artificial dyes and will continue to partner with regulators to align with future health standards.

The phase-out is part of a broader wave of changes across the industry, demonstrating how food giants are adapting to both policy shifts and consumer demands for cleaner labels.

Sometimes, the most exciting opportunities are hiding in plain sight.

The numbers are clear, but the market hasn’t caught on yet.

This undervalued company is taking on a sector with unlimited potential: public safety.

Their technology is already deployed across schools, hospitals, and corporate campuses, cutting crime rates and enhancing security.

And their subscription model is a game-changer, providing 24/7 service for as little as $0.75 per hour. That’s a fraction of the cost of traditional security services.

With a low float of just 6 million shares, their shares are tightly held, creating the perfect conditions for big moves.

Investor sentiment has been building steadily, with shares trending up since mid-October.

This is more than just a robotics company—it’s a leader in a sector ready to explode.

Discover the company now.

Verve Therapeutics (NASDAQ: VERV) is set for a significant shift after Eli Lilly announced plans to acquire the gene-editing company in a deal valued at up to $1.3 billion.

The agreement marks a significant move in the biotech space as large pharmaceutical firms seek to secure promising gene-editing technologies to strengthen their pipelines.

The transaction includes a base payment along with a performance-based component tied to clinical milestones.

This acquisition centers on Verve’s leading program, which utilizes gene editing to permanently inactivate the PCSK9 gene, a key target in controlling LDL cholesterol.

The innovative approach aligns with the growing demand for one-time treatments for cardiovascular disease.

Eli Lilly’s decision to acquire Verve builds on their existing collaboration and signals a commitment to advancing gene-editing therapies beyond early-stage trials.

For current shareholders, this buyout offers a premium and a clear exit opportunity in a volatile sector.

The deal brings financial certainty while highlighting the broader market’s recognition of Verve’s technology potential.

Investors holding shares will want to monitor how smoothly the deal closes and whether it triggers further consolidation among smaller gene-editing firms.

Those evaluating a future position in this space should consider what this transaction signals: a large pharma company’s increasing appetite for gene-editing innovation.

The move underscores the growing importance of gene editing in cardiovascular care and could drive renewed interest across the sector.

Momentum like this could set the stage for deeper integration of gene editing into mainstream healthcare strategies.

CERo Therapeutics Holdings Inc [CERO] $19.83 (+191.62%)

CERo Therapeutics surged after its lead drug candidate for acute myeloid leukemia received Orphan Drug Designation from the FDA, boosting confidence in accelerated development.

Eyenovia Inc [EYEN] $6.97 (+134.68%)

Eyenovia rallied after announcing a $50 million private placement to buy HYPE tokens and rebrand as a crypto-oriented company, becoming the first Nasdaq-listed validator for the Hyperliquid chain.

Robin Energy Ltd [RBNE] $10.59 (+91.85%)

Robin Energy was driven by oil prices, which gained over 4% amid escalating Israel-Iran tensions and heightened fears of global supply disruptions.

Sunrun Inc [RUN] $5.78 (-40.04%)

Sunrun plunged after a Senate tax proposal threatened to phase out solar energy incentives by 2028, undermining long-term demand and profitability for rooftop solar companies.

SolarEdge Tech [SEDG] $15.96 (-33.44%)

SolarEdge is another casualty of the Senate’s draft tax bill, as markets reacted to the potential early end of solar subsidies.

Dyne Therapeutics Inc [DYN] $10.86 (-21.42%)

Dyne Therapeutics dropped after revising its trial endpoint for its lead drug, raising concerns about regulatory uncertainty and a delayed approval timeline.

As demand for clean energy and safe-haven assets grows, one company is advancing both uranium and gold — in a region built for mining success.

With the energy transition accelerating and gold near all-time highs, this opportunity is too strategic to ignore.

Click here to learn more about this dual-resource breakthrough.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.